


CLAIMS:

1. A chemical compound represented by general formula (I)



or a pharmaceutically acceptable salt thereof, wherein

- 10 R^0 , R^m and R^p independently of each other represent
hydrogen, halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy;
with the proviso that not all three of R^0 , R^m and R^p represent hydrogen;

- R^2 , R^3 , R^4 and R^5 independently of each other represent
hydrogen, halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy;
- 15 with the proviso that the compound is not
N-(3-Trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-
urea.

2. The compound of claim 1, wherein
- 20 R^0 represents hydrogen;
 R^m represents hydrogen; and
 R^p represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.

3. The compound of claim 1, wherein
- 25 R^0 represents hydrogen;
 R^p represents hydrogen; and
 R^m represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.

4. The compound of any one of claims 1-3, wherein
- 30 R^3 , R^4 and R^5 represent hydrogen; and
 R^2 represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.

5. The compound of any one of claims 1-3, wherein
 R^2 , R^4 and R^5 represent hydrogen; and
 R^3 represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.
- 5 6. The compound of any one of claims 1-3, wherein
 R^2 , R^3 and R^5 represent hydrogen; and
 R^4 represents halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.
7. The compound of any one of claims 1-3, wherein
10 R^2 and R^5 represent hydrogen; and
 R^3 and R^4 independently of each other represent halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.
8. The compound of any one of claims 1-3, wherein
15 R^2 and R^4 represent hydrogen; and
 R^3 and R^5 independently of each other represent halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy.
9. The compound of claim 1, being
20 *N*-(4-Chloro-3-trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
N-(3-Trifluoromethyl-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
N-(4-Chloro-3-trifluoromethyl-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
25 *N*-(3,5-Dichloro-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
N-(3,5-Difluoro-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
N-(3,5-Dichloro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
N-(3,5-Difluoro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
N-(3-Trifluoromethyl-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-5-yl]-urea;
30 *N*-(4-Chloro-3-trifluoromethyl-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
N-(3,5-Dichloro-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
N-(3,5-Difluoro-phenyl)-*N'*-[4'-fluoro-2-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
N-(4-Fluoro-3-trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
35 *N*-(3,5-Bis-trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
N-(3,5-Bis-trifluoromethyl-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;

- N*-(4-Fluoro-3-trifluoromethyl-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(3,5-Bis-trifluoromethyl-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- 5 *N*-(4-Fluoro-3-trifluoromethyl-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
- N*-(2-Trifluoromethyl-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- 10 *N*-(2-Bromo-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
- N*-(2-Trifluoromethyl-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Bromo-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Bromo-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Fluoro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
- 15 *N*-(2-Fluoro-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Fluoro-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Fluoro-phenyl)-*N'*-[4'-methyl-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Chloro-phenyl)-*N'*-[4'-methyl-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Bromo-phenyl)-*N'*-[4'-methyl-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- 20 *N*-(2-Trifluoromethyl-phenyl)-*N'*-[4'-methyl-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Chloro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
- N*-(2-Chloro-phenyl)-*N'*-[4'-chloro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(2-Chloro-phenyl)-*N'*-[4'-fluoro-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(3,5-Dichloro-phenyl)-*N'*-[4'-methoxy-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- 25 *N*-(3,5-Difluoro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethoxy-biphenyl-4-yl]-urea;
- N*-(3,5-Dichloro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethoxy-biphenyl-4-yl]-urea;
- N*-(3,5-Bis-trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethoxy-
- 30 biphenyl-4-yl]-urea;
- N*-(3,5-Difluoro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea;
- N*-(3,5-Dichloro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea;
- N*-(3,5-Bis-trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea;
- 35 *N*-(3,5-Difluoro-phenyl)-*N'*-[4'-methoxy-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(3,5-Bis-trifluoromethyl-phenyl)-*N'*-[4'-methoxy-3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-urea;
- N*-(3-Bromo-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;
- N*-(4-Chloro-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-4'-trifluoromethyl-biphenyl-4-yl]-urea;

N- (4-Fluoro-3-trifluoromethyl-phenyl)-*N'*-[3-(1*H*-tetrazol-5-yl)-3'-trifluoromethyl-biphenyl-4-yl]-urea;
or a pharmaceutically acceptable salt thereof.

- 5 10. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any of claims 1-9, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
- 10 11. The use of a compound according to any one of claims 1-9, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to the blockade of chloride channels.
- 15 12. The use according to claim 11, wherein the disease, disorder or condition responsive to the blockade of chloride channels is a bone metabolic disease, an osteoclast related bone disease, or a disease, disorder or condition that is responsive to inhibition of angiogenesis.
- 20 13. A method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to responsive to the blockade of chloride channels, which method comprises the step of administering to such a living animal body in need
- 25 thereof a therapeutically effective amount of a compound according to any one of the claims 1-9, or a pharmaceutically acceptable salt thereof.